CD7 Targeted AAV Expands Immune Cell Engineering

A Nature Biotechnology paper reports an evolved AAV capsid, AAV.APR31, that enters primary human T and NK cells at approximately 100–1,000-fold lower vector doses than AAV6 and supports transient transfer, targeted knock-in and transposon…




